EP300 and metastatic melanoma: On the other hand, the percentage of cases expressing strong nuclear p300 (N-IRS 9 and 12), 39.3% in normal nevi and 46.3% in dysplastic nevi, was decreased to 25.9% in primary melanoma and 20.6% in metastatic melanoma.